Compare Abeona Therapeutics Inc (ABEO) vs AFLAC Incorporated (AFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs AFLAC Incorporated — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while AFLAC Incorporated trades at $120.88 (market cap $60.70B). The key difference: AFLAC Incorporated is far larger — about 144.1× Abeona Therapeutics Inc's market cap, and AFLAC Incorporated pays a 2.02% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AFL | |
|---|---|---|
Market Cap | $421.19M | $60.70B |
Sector | Health | Financials |
52-Week High | $7.45 | $129.55 |
52-Week Low | $4.17 | $103.55 |
Enterprise Value | $276.10M | $70.65B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
AFL trades at $121.09, down 0.7% on the day, with a bullish overall technical signal but bearish moving averages and oscillators. The stock shows strong profitability with a 26.59% net income margin and 16.91% ROE, though recent quarters have seen EPS misses. Revenue declined to $17.36B in 2025, with net income of $3.65B. Recent news highlights AFL's rebranding of network services and ongoing dividend commitments.
Outlook is mixed; solid fundamentals and a 43-year dividend growth history support income investors, but near-term headwinds include revenue pressure in Japan and FX impacts. Analyst consensus is cautious with a $118 price target below current levels, suggesting limited upside amid execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →
